Related Articles
Evaluation of erlotinib for the treatment of patients with non-small cell lung cancer with epidermal growth factor receptor wild type
Value of TTF‑1 expression in non‑squamous non‑small‑cell lung cancer for assessing docetaxel monotherapy after chemotherapy failure
Phase II study of erlotinib for previously treated patients with EGFR wild‑type non‑small‑cell lung cancer, following EGFR mutation status reevaluation with the Scorpion Amplified Refractory Mutation System
Shikonin sensitizes wild‑type EGFR NSCLC cells to erlotinib and gefitinib therapy
Clinical significance of epidermal growth factor receptor mutations and insulin-like growth factor 1 and its binding protein 3 in advanced non-squamous non-small cell lung cancer